Mouse 4T1 Breast Tumor Model

The 4T1 mammary carcinoma is a transplantable tumor cell line that is highly tumorigenic and invasive and, unlike most tumor models, can spontaneously metastasize from the primary tumor in the mammary gland to multiple distant sites including lymph nodes, blood, liver, lung, brain, and bone The 4T1 tumor has several characteristics that make it a suitable experimental animal model for human mammary cancer. First, tumor cells are easily transplanted into the mammary gland so that the primary tumor grows in the anatomically correct site, as described in this unit. Second, as in human breast cancer, 4T1 metastatic disease develops spontaneously from the primary tumor. Also, the progressive spread of 4T1 metastases to the draining lymph nodes and other organs is very similar to that of human mammary cancer. In this unit, a protocol describes surgical removal of the primary tumor, so that metastatic disease can be studied in an animal setting comparable to the clinical situation where the primary tumor is surgically removed, and metastatic foci remain intact. Another advantage of 4T1 is its resistance to 6‐thioguanine. This property enables precise quantitation of metastatic cells, even when they are disseminated and at sub‐microscopic levels in distant organs, as described here.

[1]  D. Hicklin,et al.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.

[2]  R. Mohammad,et al.  p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity. , 1998, International journal of molecular medicine.

[3]  E. Rutgers,et al.  Follow‐up after treatment of primary breast cancer , 1989, The British journal of surgery.

[4]  F. Miller,et al.  Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. , 1992, Cancer research.

[5]  M. Amer,et al.  Chemotherapy and pattern of metastases in breast cancer patients , 1982, Journal of surgical oncology.

[6]  M. Laberge [Cancer of the breast]. , 1961, Laval medical.

[7]  E. Shohami,et al.  Induction of antitumor immunity by indomethacin , 2000, Cancer Immunology, Immunotherapy.

[8]  W. Donegan,et al.  Screening for recurrent breast cancer--its effectiveness and prognostic value. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Ostrand-Rosenberg,et al.  Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon γ , 2000, Cancer Immunology, Immunotherapy.

[10]  H. Mouridsen,et al.  Incidence and methodologic aspects of the occurrence of liver metastases in recurrent breast cancer , 1987, Cancer.

[11]  J. Klingelhöfer,et al.  Transcription of a novel mouse semaphorin gene, M-semaH, correlates with the metastatic ability of mouse tumor cell lines. , 1998, Cancer research.

[12]  D. Dexter,et al.  Heterogeneity of tumor cells from a single mouse mammary tumor. , 1978, Cancer research.

[13]  M. Dewhirst,et al.  Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  B A Pulaski,et al.  Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. , 2000, Cancer research.

[15]  W. Boogerd Central nervous system metastasis in breast cancer. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  S. Ostrand-Rosenberg,et al.  Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. , 1998, Cancer research.

[17]  J. Sogn Tumor immunology: the glass is half full. , 1998, Immunity.